Wöber C, Brücke T, Wöber-Bingöl C, Asenbaum S, Wessely P, Podreka I
Department of Neurology, University of Vienna, Austria.
Cephalalgia. 1994 Jun;14(3):235-40. doi: 10.1046/j.1468-2982.1994.014003235.x.
We studied in vivo the influence of flunarizine on dopamine D2 receptors and investigated whether dopamine D2 receptor blockade is involved in its antimigraine action. Eleven migraine patients, treated with flunarizine, 10 mg per day, underwent single photon emission computer tomography (SPECT) using [123I] labeled iodobenzamide, a ligand with high affinity and high specificity for D2 receptors. There was a reduction of the dopamine D2 receptor binding potential in all patients compared to age-matched controls. The efficacy of flunarizine in migraine prophylaxis failed to correlate with the degree of the dopamine D2 receptor blockade. The antimigraine action of flunarizine may not involve antidopaminergic mechanisms.
